Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kyorin Pharmaceutical Co has the GF Score of 74, which implies that the company
is
Likely to have average performance.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Kyorin Pharmaceutical Co
is
Likely to have average performance.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Kyorin Pharmaceutical Co (OTCPK:KYRNF) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Kyorin Pharmaceutical Co GF Score Related Terms
KYRNF vs ZTS: GF Score Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kyorin Pharmaceutical Co's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyorin Pharmaceutical Co GF Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kyorin Pharmaceutical Co's GF Score distribution charts can be found below:
* The bar in red indicates where Kyorin Pharmaceutical Co's GF Score falls into.
Kyorin Pharmaceutical Co (KYRNF) has a GF Score of 74 as of Aug. 02, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Kyorin Pharmaceutical Co and its competitors. This is near median its historical median of 80.00. Over the past decade, Kyorin Pharmaceutical Co's GF Score has ranged from 32.00 to 97.00.
Is Kyorin Pharmaceutical Co's GF Score too high?
Kyorin Pharmaceutical Co's current GF Score of 74 is near median its 10-year median of 80.00. Over the past 10 years, this metric has ranged from a low of 32.00 to a high of 97.00. Overall, Kyorin Pharmaceutical Co has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Kyorin Pharmaceutical Co's GF Score compare to ZTS?
Kyorin Pharmaceutical Co's GF Score of 74 can be compared against companies in the Drug Manufacturers industry. Historically, Kyorin Pharmaceutical Co's own GF Score has ranged from 32.00 to 97.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Drug Manufacturers company?
A good GF Score depends on the Drug Manufacturers industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Kyorin Pharmaceutical Co and its competitors. Kyorin Pharmaceutical Co's current GF Score is 74, which is near median its own 10-year median of 80.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyorin Pharmaceutical Co stock overvalued right now?
Kyorin Pharmaceutical Co (KYRNF) has a current GF Score of 74. The stock's GF Value™ is $13.86, compared to a current price of $10.31 — trading 25.6% below its estimated fair value. The current GF Score is 74, which is near median its 10-year median of 80.00. Kyorin Pharmaceutical Co's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Kyorin Pharmaceutical Co (KYRNF), the current GF Score is 74 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyorin Pharmaceutical Co (KYRNF) Overvalued in 2026?
Based on GuruFocus' analysis, Kyorin Pharmaceutical Co stock appears to be undervalued.
The current stock price of $10.31 is trading 25.6% below its estimated GF Value™ of $13.86.
Key valuation signals for KYRNF:
GF Score: 74 (near median its 10-year median of 80.00)
GF Value™: $13.86 vs. price of $10.31 (25.6% below fair value)
No single metric tells the full story. See the KYRNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.
74GF Score
Get the complete analysis for KYRNF
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KYRNF has been successfully added to your 
